SG10201501561XA - Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination - Google Patents

Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination

Info

Publication number
SG10201501561XA
SG10201501561XA SG10201501561XA SG10201501561XA SG10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA SG 10201501561X A SG10201501561X A SG 10201501561XA
Authority
SG
Singapore
Prior art keywords
vaccination
prevention
treatment
antibody therapy
cancers associated
Prior art date
Application number
SG10201501561XA
Other languages
English (en)
Inventor
Qi Zeng
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG10201501561XA publication Critical patent/SG10201501561XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201501561XA 2009-11-30 2010-11-30 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination SG10201501561XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26489209P 2009-11-30 2009-11-30
US34521910P 2010-05-17 2010-05-17

Publications (1)

Publication Number Publication Date
SG10201501561XA true SG10201501561XA (en) 2015-04-29

Family

ID=44066805

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201501561XA SG10201501561XA (en) 2009-11-30 2010-11-30 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
SG2012039368A SG181113A1 (en) 2009-11-30 2010-11-30 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012039368A SG181113A1 (en) 2009-11-30 2010-11-30 Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination

Country Status (4)

Country Link
EP (1) EP2506864B1 (fr)
CN (1) CN102753191B (fr)
SG (2) SG10201501561XA (fr)
WO (1) WO2011065923A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258676B2 (en) 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
WO2013063613A2 (fr) * 2011-10-28 2013-05-02 University Of Maryland Procédés et compositions associés à la neutralisation intracellulaire par une igg
WO2017217934A1 (fr) * 2016-06-14 2017-12-21 Agency For Science, Technology And Research Anticorps anti-prl3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
CN102847148A (zh) * 2007-05-03 2013-01-02 新加坡科技研究局 结合细胞内prl-1多肽或prl-3多肽的抗体
EP2185176B1 (fr) * 2007-08-10 2016-07-06 Agency for Science, Technology And Research Vhz dans le diagnostic et le traitement du cancer

Also Published As

Publication number Publication date
CN102753191A (zh) 2012-10-24
EP2506864B1 (fr) 2016-07-27
SG181113A1 (en) 2012-07-30
WO2011065923A1 (fr) 2011-06-03
CN102753191B (zh) 2016-08-24
EP2506864A4 (fr) 2013-08-21
EP2506864A1 (fr) 2012-10-10

Similar Documents

Publication Publication Date Title
HK1245119A1 (zh) 使用抗-內皮因子抗體和抗-vegf劑聯合治療癌症
HK1245128A1 (zh) 針對人腸道病毒的抗原及疫苗
HK1200740A1 (en) Combination therapy of antibodies against human csf-1r and uses thereof csf-1r
PL2619576T3 (pl) Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
IL215402A0 (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
ZA201107128B (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
EP2844736A4 (fr) Bactéries modifiées et leurs utilisations pour le traitement d'un cancer ou d'une tumeur
ZA201106730B (en) Methods of treatment using combination therapy
EP2627333A4 (fr) Traitement combine du cancer
EP2591363A4 (fr) Diagnostic et traitement du cancer du sein
EP2652508A4 (fr) Utilisation d'anticorps anti-cxcl13 et anti-cxcr5 pour le traitement ou la détection du cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
ZA201307641B (en) Human tissue factor antibody and uses thereof
EP2700652A4 (fr) Diagnostic et traitement du cancer à l'aide d'un anticorps anti-itm2a
HK1201154A1 (en) Combination therapy using anti-cd20 antibody and human il-15 cd20 il-15
ZA201300762B (en) Novel combination therapy for the treatment of cancer
EP2420515A4 (fr) Diagnostic et traitement du cancer au moyen d'un anticorps anti-tmprss11e
SG10201608967WA (en) Cancer stem cell-targeted and drug resistant cancer therapy
SG10201501561XA (en) Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
GB201412831D0 (en) Detection and treatment of breast cancer
GB201017356D0 (en) Combination treatment of cancer